The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.